Mode
Text Size
Log in / Sign up
Phase 1 N=32 Randomized Double-blind Treatment

Effects Multimodal Mind and Body Approach for MCI

Mild Cognitive Impairment

Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcome: Primary: Retention — 11; 15 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 1
Interventions
Experimental: A computer-based multimodal mind and body approach (cbMMBA) (Behavioral); A standard cognitive training group (Behavioral)
Age
Adult, Older Adult · 50+ yrs
Sex
All
Sponsor
Massachusetts General Hospital
Primary completion
Apr 2025

Outcome Measures

OutcomeResultp-value
PRIMARY
Retention
11; 15
PRIMARY
Fidelity
25.6; 29.5
PRIMARY
Satisfaction to Intervention
4.8; 4.5
PRIMARY
Number of Participants With Adverse Events
2; 0

Summary

The aim of this application is to develop a computer-based multimodal mind and body approach (CMMBA) for mild cognitive impairment (MCI). This product will provide a new, cost-effective and easily accessible treatment option for MCI and potentially other age-related dementia.

Eligibility Criteria

Inclusion Criteria

  • report of cognitive decline / complaint by the patient, the patient's informant, or the physician;
  • cognitive impairment is confirmed by objective cognitive measures (Montreal Cognitive Assessment (MoCA) and neuropsychological testing), where objective cognitive impairment is defined as poor performance in one or more cognitive measures suggesting deficit in one or more cognitive domains;
  • patient has preserved independence in functional abilities (measured by informant report, completion of Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) checklists);
  • not demented;

Exclusion Criteria

  • has severe visual or hearing impairment;
  • has pre-existing musculoskeletal or other conditions, which prohibit BDJ performance and / or the application of acupressure at the selected points;
  • has suffered from a neurological disorder (e.g., severe head trauma), psychiatric disease (e.g., major depression), or any other major medical disease that could potentially compromise their cognition;
  • has had prior experience with BDJ or acupressure or relaxation techniques in the past year.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06814483). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search